Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc., headquartered in the United States, is a leading player in the pharmaceutical industry, specialising in innovative therapies for dermatological and ophthalmic conditions. Founded in 2014, the company has made significant strides in developing unique formulations that leverage the power of hypochlorous acid, setting it apart in the market. With a focus on wound care, skin care, and eye care, Sonoma's core products, including its patented Alevicyn® and Alevicyn® Eye Drops, are designed to promote healing while minimising irritation. The company has established a strong market position, recognised for its commitment to quality and efficacy. Sonoma Pharmaceuticals continues to expand its operational reach, aiming to improve patient outcomes globally through its advanced therapeutic solutions.
DitchCarbon Score
How does Sonoma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sonoma Pharmaceuticals's score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sonoma Pharmaceuticals's reported carbon emissions
Sonoma Pharmaceuticals, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it outline specific reduction targets or initiatives. Without concrete figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, the absence of emissions data and defined reduction strategies may reflect a broader industry context where many companies are increasingly prioritising climate action and transparency. As the focus on environmental responsibility grows, it will be essential for Sonoma Pharmaceuticals to establish and communicate its climate commitments to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sonoma Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
